Evogene and Zeraim Gedera Salt Tolerant Tomato Collaboration Advances to Second Phase

05-Sep-2007

Evogene Ltd. and Zeraim Gedera Ltd, which was recently acquired by Syngenta S.A., announced that their joint program for the development of salt tolerant tomato varieties has successfully completed the first phase with experimental varieties currently undergoing field trials in target locations worldwide.

Under a recently signed follow-on agreement, the parties intend to further develop the experimental varieties towards commercialization and develop additional varieties for new target markets. The use of massive irrigation practices and water sources of high salinity levels in tomato growing areas have caused a reduction in tomato yield and in severe cases the abandoning of such areas. The tomato varieties developed through this collaboration are expected to allow growers to maintain high yields under severe growing conditions displaying high salt concentrations of water and soil.

Zeraim Gedera's breeding program is based on its tomato germplasm and utilizes Evogene's advanced selection tools. These selection tools include proprietary selection assays and molecular marker for salt tolerance, developed based on Evogene's computational gene discovery platform.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Heptares granted patents covering stabilised receptor technology in Europe and Japan - Key patent grants protect Heptares’ leading position in GPCR-targeted drug design and discovery

Pevion’s therapeutic Candida vaccine shows robust systemic and mucosal immunogenicity

Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics

Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics

Amarin corporation Appoints Colin W. Stewart as President and Chief Executive Officer

Discovery of quantum vibrations in 'microtubules' corroborates theory of consciousness

Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”

Merck Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million - “Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems”

Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration

A sprinkle of platinum nanoparticles onto graphene makes brain probes more sensitive

A sprinkle of platinum nanoparticles onto graphene makes brain probes more sensitive

Merck and Washington University working on diagnostics and treatment of malnutrition - Genome editing to be used in intestinal bacteria research

Biophage Pharma announces sale of Immunotox Labs Division to Validapro BioSciences Inc

Rescue for Sardines and Anchovies: Produce DHA through biotechnology using microalgae

Rescue for Sardines and Anchovies: Produce DHA through biotechnology using microalgae

Astex reveals structure of key drug metabolizing enzyme - cytochrome P450 3A4 - in Science